MX363118B - Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). - Google Patents

Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Info

Publication number
MX363118B
MX363118B MX2014012945A MX2014012945A MX363118B MX 363118 B MX363118 B MX 363118B MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 363118 B MX363118 B MX 363118B
Authority
MX
Mexico
Prior art keywords
aminopyrimidine derivatives
lrrk2
pyrazole
modulators
lrrk2 modulators
Prior art date
Application number
MX2014012945A
Other languages
English (en)
Other versions
MX2014012945A (es
Inventor
Chen Huifen
Baker-Glenn Charles
Chambers Mark
K Chan Bryan
Estrada Anthony
Jon Burdick Daniel
Kevin Sweeney Zachary
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2014012945A publication Critical patent/MX2014012945A/es
Publication of MX363118B publication Critical patent/MX363118B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se relaciona con compuestos de pirazol que son moduladores de LRRK2, con métodos para elaborar los compuestos, y con métodos para usar los compuestos para el tratamiento de enfermedades asociadas con el receptor LRRK2, tal como la enfermedad de Parkinson.
MX2014012945A 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). MX363118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642019P 2012-05-03 2012-05-03
PCT/EP2013/058939 WO2013164321A1 (en) 2012-05-03 2013-04-30 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (2)

Publication Number Publication Date
MX2014012945A MX2014012945A (es) 2015-02-10
MX363118B true MX363118B (es) 2019-03-11

Family

ID=48325675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012945A MX363118B (es) 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Country Status (11)

Country Link
US (1) US9212173B2 (es)
EP (1) EP2844652B1 (es)
JP (1) JP6218808B2 (es)
KR (1) KR102091894B1 (es)
CN (2) CN104271569B (es)
BR (1) BR112014026952B1 (es)
CA (1) CA2870049C (es)
HK (1) HK1200820A1 (es)
MX (1) MX363118B (es)
RU (1) RU2637947C2 (es)
WO (1) WO2013164321A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279202A (zh) * 2012-05-03 2017-01-04 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物
NZ702571A (en) 2012-06-29 2017-02-24 Pfizer 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
MX2016007898A (es) 2013-12-20 2016-10-07 Signal Pharm Llc Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos.
ES2717757T3 (es) 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compuestos
CN105940004B (zh) 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 化合物
CN107074814A (zh) * 2014-07-24 2017-08-18 拜耳制药股份公司 葡萄糖转运抑制剂
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CR20220182A (es) 2016-06-16 2022-06-15 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592)
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
KR20200089713A (ko) 2017-11-21 2020-07-27 데날리 테라퓨틱스 인크. 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법
MX2020006641A (es) 2017-12-20 2021-01-08 Denali Therapeutics Inc Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
CN111936573A (zh) 2018-02-14 2020-11-13 大阪有机化学工业株式会社 用于形成耐热性且易剥离性的固化树脂膜的固化性树脂组合物及其制造方法
WO2019160037A1 (ja) * 2018-02-14 2019-08-22 国立大学法人 東京大学 酸ハロゲン化物による化合物の製造方法
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
US11130752B2 (en) 2018-09-25 2021-09-28 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
WO2020187292A1 (zh) * 2019-03-19 2020-09-24 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN116685325A (zh) 2020-10-20 2023-09-01 豪夫迈·罗氏有限公司 Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422371C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
EP2440548A1 (en) * 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
CA2797947C (en) * 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
CA2809836C (en) * 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
HUE037844T2 (hu) * 2010-11-10 2018-09-28 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
RU2014109897A (ru) * 2011-08-25 2015-09-27 Ф.Хоффманн-Ля Рош Аг Ингибиторы серин/треонин киназы рак1
WO2013067264A1 (en) * 2011-11-03 2013-05-10 Genentech, Inc. 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
SI2820009T1 (en) * 2012-03-01 2018-05-31 Array Biopharma, Inc. Serine / Threonine kinase inhibitors
KR102281288B1 (ko) * 2012-09-26 2021-07-26 에프. 호프만-라 로슈 아게 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
EP2991978A4 (en) * 2013-05-01 2016-09-14 Hoffmann La Roche BIHETEROARYL COMPOUNDS AND USES THEREOF

Also Published As

Publication number Publication date
HK1200820A1 (zh) 2015-08-14
BR112014026952B1 (pt) 2022-03-15
RU2014147381A (ru) 2016-06-27
KR20150016532A (ko) 2015-02-12
CN104271569A (zh) 2015-01-07
US20150051238A1 (en) 2015-02-19
EP2844652A1 (en) 2015-03-11
WO2013164321A1 (en) 2013-11-07
US9212173B2 (en) 2015-12-15
KR102091894B1 (ko) 2020-03-20
BR112014026952A8 (pt) 2021-06-15
MX2014012945A (es) 2015-02-10
JP6218808B2 (ja) 2017-10-25
CA2870049A1 (en) 2013-11-07
CA2870049C (en) 2020-12-29
EP2844652B1 (en) 2019-03-13
JP2015515966A (ja) 2015-06-04
CN106220615A (zh) 2016-12-14
RU2637947C2 (ru) 2017-12-08
CN104271569B (zh) 2016-08-24
BR112014026952A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
NZ737399A (en) Ccr2 modulators
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
HK1195309A1 (zh) 作為激酶 調節劑用於治療帕金森病的 -苯基氨基嘧啶衍生物
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
SG194718A1 (en) Novel compounds as modulators of protein kinases
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015000129A (es) Derivados de pirimidin pirazolilo.
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
RS55370B1 (sr) 2-(fenil ili pirid-3-il)aminopirimidinski derivati kao modulatori lrrk2 kinaze za lečenje parkinsonove bolesti
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).